close
Jump to content

Lysergic acid 2-pentylamide

From Wikipedia, the free encyclopedia

Lysergic acid 2-pentylamide
BERJAYA
Clinical data
Other names2-LSP; N-(Pentan-2-yl)lysergamide; N-Pentan-2-yllysergamide; N-(2-Pentyl)lysergamide; N-(sec-Pentyl)lysergamide; N2Pe-LA; Lysergic acid 2-pentylamide; N-(2-Amyl)lysergamide; 6-Methyl-N-(pentan-2-yl)-9,10-didehydroergoline-8β-carboxamide; 2-APLA
Drug classSerotonin receptor modulator
ATC code
  • None
Identifiers
  • (6aR,9R)-7-methyl-N-pentan-2-yl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC21H27N3O
Molar mass337.467 g·mol−1
3D model (JSmol)
  • CCCC(C)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C
  • InChI=1S/C21H27N3O/c1-4-6-13(2)23-21(25)15-9-17-16-7-5-8-18-20(16)14(11-22-18)10-19(17)24(3)12-15/h5,7-9,11,13,15,19,22H,4,6,10,12H2,1-3H3,(H,23,25)/t13?,15-,19-/m1/s1
  • Key:JGLCNUHMSLNTLJ-NWLOPNIYSA-N

Lysergic acid 2-pentylamide (2-LSP), also known as N-(2-pentyl)lysergamide (N2Pe-LA), is a serotonin receptor modulator and possible psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).[1][2][3][4][5][6] It is a mixture of (R)- and (S)- enantiomers.[1][7][5]

Both enantiomers of 2-LSP show affinity for the serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors, but (R)-2-LSP shows far greater affinity for these receptors in comparison.[3][2][7][6] (R)-2-LSP had about the same affinity as LSD for the serotonin 5-HT2A receptor (Ki = 4.5–10 nM; K0.5 = 0.99–1.0 nM), but had 0.8- to 9-fold higher affinity than LSD for the serotonin 5-HT1A receptor (Ki = 0.6–1.4 nM; K0.5 = 0.37 nM).[3][2][1][7][5][6] Both (R)- and (S)-2-LSP act as full agonists of the serotonin 5-HT2A receptor, but (R)-LSP is nearly 20-fold more potent than (S)-LSP in this regard EC50Tooltip half-maximal effective concentration (EmaxTooltip maximal efficacy) = 5.4 nM (100%) and 91 nM (100%), respectively).[3][2][7] Both enantiomers are also serotonin 5-HT2C receptor agonists, with (R)-LSP likewise being much more active than (S)-LSP.[7] (R)-2-LSP fully substituted for LSD in rodent drug discrimination tests, with about half the potency of LSD.[1][2][3][7][5] Conversely, (S)-2-LSP did not substitute for LSD in these tests.[1][2][3][7]

The chemical synthesis of 2-LSP has been described.[7]

2-LSP was first described in the scientific literature by David E. Nichols and colleagues by 1995.[7]

See also

[edit]

References

[edit]
  1. 1 2 3 4 5 Nichols DE (2001). "LSD and Its Lysergamide Cousins" (PDF). The Heffter Review of Psychedelic Research. 2. Heffter Research Institute: 80–87. ISSN 1534-9640.
  2. 1 2 3 4 5 6 Nichols DE (2018). Chemistry and Structure-Activity Relationships of Psychedelics. Current Topics in Behavioral Neurosciences. Vol. 36. pp. 1–43. doi:10.1007/7854_2017_475. ISBN 978-3-662-55878-2. PMID 28401524. This approach was extended to study of a series of chiral 2-aminoalkane amides of lysergic acid, with the alkyl group extended from butyl to heptyl (Monte et al. 1995). Using [3 H]ketanserin displacement from rat frontal cortex homogenate to measure 5-HT2A receptor affinity, the lysergamide with the R-configuration in the secondary alkyl amide group had higher affinity in every case than the one with the S configuration. As the chain length increased affinity decreased, with the R-2-heptylamide having a Ki of only 80 nM. The pentyl isomers of 26 were the only compounds tested in functional assays, where each isomer proved to be a full agonist in the PI hydrolysis assay, but the S-isomer was less potent (see Table 1). Surprisingly, however, extending the length of the 2-alkyl group of the amide increased 5-HT1A receptor affinity, with the R-2-hexyl substituted amide having a Ki of 0.32 nM! Clearly, the 5-HT1A receptor has greater tolerance for bulk attached to the amide. Tests in rats trained to discriminate LSD from saline showed that full substitution occurred with the R-2-pentyl lysergamide 26, but not with the S-pentyl, hexyl, or heptyl compounds. In vitro affinities observed at the rat 5-HT2A receptor parallel these in vivo results.
  3. 1 2 3 4 5 6 Nichols DE (2012). "Structure–activity relationships of serotonin 5-HT 2A agonists". Wiley Interdisciplinary Reviews: Membrane Transport and Signaling. 1 (5): 559–579. doi:10.1002/wmts.42. ISSN 2190-460X. Retrieved 22 March 2025.
  4. Shulgin A, Shulgin A (September 1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252. https://erowid.org/library/books_online/tihkal/tihkal26.shtml [...] "N-Pentan-2-yllysergamide" [...]
  5. 1 2 3 4 Nichols DE, Monte A, Huang X, Marona-Lewicka D (1996). "Stereoselective pharmacological effects of lysergic acid amides possessing chirality in the amide substituent". Behavioural Brain Research. 73 (1–2): 117–119. doi:10.1016/0166-4328(96)00080-0. PMID 8788487. The most potent LSD-like compound, with greatest similarity to LSD itself in all the bioassays was the lysergamide prepared from (R)-2- aminobutane (see Table 2). In vivo activity in the drug discrimination assay rapidly drops off when the alkyl group is extended to the next higher homolog, the (R)- 2-aminopentane derivative, even though affinity for the ketanserin-labeled 5-HT2A receptor is comparable to that of LSD, and affinity for the 5-HT1A receptor is increased about 7- or 8-fold.
  6. 1 2 3 McCorvy JD (16 January 2013). Mapping the binding site of the 5-HT2A receptor using mutagenesis and ligand libraries: Insights into the molecular actions of psychedelics (Ph.D. thesis). Purdue University. Archived from the original on 15 May 2025. Retrieved 27 May 2025 via Purdue e-Pubs.{{cite thesis}}: CS1 maint: bot: original URL status unknown (link)
  7. 1 2 3 4 5 6 7 8 9 Monte AP, Marona-Lewicka D, Kanthasamy A, Sanders-Bush E, Nichols DE (March 1995). "Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes". Journal of Medicinal Chemistry. 38 (6): 958–966. doi:10.1021/jm00006a015. PMID 7699712.
[edit]